Last reviewed · How we verify
NCT03327025
Survivor Health and Resilience Education
NA trial testing Health education counseling in Pediatric Cancer in 17 participants. Completed in 29 March 2017.
29 March 2017
Quick facts
| Lead sponsor | Georgetown University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 17 |
| Start date | 19 July 2013 |
| Primary completion | 29 March 2017 |
| Estimated completion | 29 March 2017 |
Drugs / interventions tested
- Health education counseling
Conditions studied
- Pediatric Cancer — all drugs for Pediatric Cancer →
Sponsor
Georgetown University
Who can join
Adults 8 to 25, any sex, with Pediatric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An intervention to assist pediatric cancer survivors to behaviorally manage late effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03327025
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pediatric Cancer
Currently open trials in the same condition.
- NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
- NCT07278778 — Cancer Care Companion · NA · recruiting
- NCT07473518 — Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy · recruiting
- NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
- NCT07188311 — Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma · NA · recruiting
Other Georgetown University trials
Trials by the same sponsor.
- NCT07228000 — Bundled Cancer Screening and Genetic Services Navigation · NA · not yet recruiting
- NCT07128927 — Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors · NA · recruiting
- NCT06046287 — Daratumumab for Polyneuropathy Associated With MGUS · Phase 2 · withdrawn
- NCT06980103 — Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyro · NA · recruiting
- NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03327025 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Georgetown University
- Last refreshed: 31 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03327025.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing